Compare Abeona Therapeutics Inc (ABEO) vs eBay Inc (EBAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs eBay Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M), while eBay Inc trades at $106.25 (market cap $47.93B). The key difference: eBay Inc is far larger — about 113× Abeona Therapeutics Inc's market cap, and eBay Inc pays a 1.15% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | EBAY | |
|---|---|---|
Market Cap | $424.33M | $47.93B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.45 | $118.96 |
52-Week Low | $4.17 | $79.41 |
Enterprise Value | $279.23M | $51.75B |
Volume | — | 5,186,418 |
Dividend Yield | — | 1.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
EBAY trades at $111.98, up 1.67% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals, including a net income margin of 18.57% and ROE of 47.38%, supported by revenue growth to $11.10B in 2025. Recent news highlights potential partnership talks with GameStop after a withdrawn $56B bid, adding volatility but strategic interest.
Outlook is positive with a consensus price target of $119.85, indicating ~7% upside, driven by earnings momentum and focus category growth. Risks include competitive pressures in e-commerce and market sensitivity to merger speculation. Investors may find value in sustained profitability and analyst buy ratings, though monitor execution on guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About eBay Inc
eBay Inc. is a global commerce company. The Company's platforms are designed to enable sellers worldwide to organize and offer their inventory for sale and buyers to find and buy it. eBay's items can be new or used, plain or luxurious, commonplace or rare, trendy or one-of-a-kind.
Read more on EBAY →
